6984
R. V. S. Nirogi et al. / Bioorg. Med. Chem. Lett. 22 (2012) 6980–6985
Table 4
a
The pharmacokinetic profile of 15e in male wistar rats
Compound 15e
Route
n
Dose (mg/kg)
Cmax (ng/mL)
AUC (ng.hr/mL)
t1/2 (hr)
Vd (L/kg)
Cl (mL/min/kg)
F (%)
26
p.o.
i.v.
3
3
10
10
90 35
928 378
544 236
2116 135
7.67 2.8
3.86 1.05
21.95 12.52
24.26 6.25
331.35 179.75
73.78 12.21
a
Fasted male wistar rats, vehicle used: water for injection for both oral and iv routes. Dosing volumes: 10 mL/kg for oral and 2 mL/kg for iv.
Open column - Familiar object
Filled column - Novel object
20
10
0
*
*
**
*
//
Vehicle
2 mL/kg, p.o.
Compound 15e
1 mg/kg, p.o.
Compound 15e
3 mg/kg, p.o.
Donepezil
1 mg/kg, p.o.
Compound 15e
10 mg/kg, p.o.
Figure 3. Novel object recognition test data for compound 15e in rats. ⁄⁄p < 0.01, ⁄p < 0.05 versus familiar object (Paired t test), n = 8–10/group, p.o., dosing; 60 min prior to
test. Vehicle-Water for injection 2 mL/kg, p.o.
10. Mitchell, E. S. Int. Rev. Neurobiol. 2011, 96, 163.
11. Ivachtchenko, A. V.; Golovina, E. S.; Kadieva, M. G.; Kysil, V. M.; Mitkin, O. D.;
procognitive potential of selective CNS penetrant 5-HT6
antagonists.
Tkachenko, S. E.; Okun, I. Bioorg. Med. Chem. 2011, 19, 1482.
In summary, we have disclosed a series of novel N,N-dimethyl-
[9-(arylsulfonyl)-2,3,4,9-tetrahydro-1H-carbazol-3-yl] amines as
potent and selective 5-HT6 receptor antagonists. From the results
discussed above, it is evident that cyclization of the side-chain
bearing terminal nitrogen with C2 of indole nucleus was very well
tolerated. Selected lead compound, 15e was efficacious in animal
models like NORT confirming the memory enhancing properties.
These data further support the potential utility of 5-HT6 receptor
antagonists for the treatment of psychiatric and neurological disor-
ders associated with cognitive dysfunction.
12. Alexandre, V.; Elena, S. G.; Madina, G. K.; Volodymyr, M. K.; Oleg, D. M.; Sergey,
E. T.; Ilya, M. O. J. Med. Chem. 2011, 54, 8161.
13. Sleight, A. J.; Boess, F. G.; Bos, M.; Levet-Trafit, B.; Riemer, C.; Bourson, A. Br. J.
Pharmacol. 1998, 124, 556.
14. de Bruin, N. M. W. J.; Kloeze, B. M.; McCreary, A. C. Neuropharmacology 2011,
61, 451.
15. Perez, G. G. Pharmacol., Biochem. Behav. 2005, 81, 673.
16. Maher-Edwards, G.; Zvartau-Hind, M.; Hunter, A. J.; Gold, M.; Hopton, G.;
Jacobs, G.; Davy, M.; Williams, P. Curr. Alzheimer Res. 2010, 7, 374.
17. Arnt, J.; Bang-Andersen, B.; Grayson, B.; Bymaster, F. P.; Cohen, M. P.; DeLapp,
N. W.; Giethlen, B.; Kreilgaard, M.; McKinzie, D. L.; Neill, J. C.; Nelson, D. L.;
Nielsen, S. M.; Poulsen, M. N.; Schaus, J. M.; Witten, L. M. Int. J.
Neuropsychopharmacol. 2010, 13, 1083.
18. Thomas, C.; Kenneth, Z.; Evan, M.; Jeremias, A.; Joanne, B.; Bill, B.; Tracey, B.;
Irene, E.; Yiyun, H.; James, K.; Kyle, K.; Tarek, L.; Nabeel, N.; Beata, P. W.; Anna,
P.; Marc, S.; Grace, V.; Richard, C.; Elyse, K.; Timothy, M. C. Alzheimer’s Demen.
2011, 7, S794.
19. Nirogi, R.; Kandikere, V.; Mudigonda, K.; Bhyrapuneni, G.; Shinde, A.;
Kambhampati, R.; Jayarajan, P.; Abraham, R.; Mulla, M. S.; Muddana, N.;
Benade, V.; Saralaya, R. Alzheimer’s Demen. 2011, 7, S659.
20. Tsai, Y.; Dukat, M.; Slassi, A.; MacLean, N.; Demchyshyn, L.; Savage, J. E.; Roth,
B. L.; Hufesein, S.; Lee, M.; Glennon, R. A. Bioorg. Med. Chem. Lett. 2000, 10,
2295.
21. Russell, M. G. N.; Baker, R. J.; Barden, L.; Beer, M. S.; Bristow, L.; Broughton, H.
B.; Knowles, M.; McAllister, G.; Patel, S.; Castro, J. L. J. Med. Chem. 2001, 44,
3881.
22. Cole, D. C.; Mahwah, M. A. US Patent 20,050,101,596.
23. Glennon, R. A.; Uma, S.; Bryan, L.; Roth, R. K.; Mikhail, L. B.; Donald, S.; Mase, L.;
Dukat, M. Curr. Top. Med. Chem. 2010, 10, 579.
Acknowledgments
The support received from discovery analytical department and
Mr. Venkateswarlu Jasti, CEO, Suven Life Sciences Ltd., Hyderabad
is gratefully acknowledged
Supplementary data
Supplementary data associated with this article can be found,
24. Liu, K. G.; Lo, J. R.; Comery, T. A.; Zhang, G. M.; Zhang, J. Y.; Kowal, D. M.; Smith,
D. L.; Di, L.; Kerns, E. H.; Schechter, L. E.; Robichaud, A. J. Bioorg. Med. Chem. Lett.
2008, 18, 3929.
References and notes
25. Glennon, R. A.; Lee, M.; Rangisetty, J. B.; Dukat, M.; Roth, B. L.; Savage, J. E.;
McBride, A.; Rauser, L.; Hufeisen, S.; Lee, D. K. J. Med. Chem. 2000, 43, 1011.
26. Jian-Min, F.U. WO Patent 2,003,030,901.
27. Slassi, A.; Edwards, L.; O’Brien, A.; Xin, T.; Tehim, A. WO patent 9,947,516.
28. Nirogi, R.; Dwarampudi, A.; Kambhampati, R.; Bhatta, V.; Kota, L.; Shinde, A.;
Badange, R.; Jayarajan, P.; Bhyrapuneni, G.; Dubey, P. K. Bioorg. Med. Chem. Lett.
2011, 21, 4577.
29. Holenz, J.; Pauwels, P. J.; Diaz, J. L.; Merce, R.; Codony, X.; Buschmann, H. Drug
Discovery Today 2006, 11, 283.
30. Nirogi, R. V.; Kambhampati, R.; Kothmirkar, P.; Konda, J. B.; Bandyala, T.; Gudla,
P.; Arepalli, S.; Pamuleti, N. G.; Shinde, A. K.; Deshpande, A. D.; Dwarampudi,
A.; Chindhe, A. K.; Dubey, P. K. Enzyme Inhib. Med. Chem. 2011. http://
1. Barnes, N. M.; Sharp, T. Neuropharmacology 1999, 38, 1083.
2. Hoyer, D.; Hannon, J. P.; Martin, G. R. Pharmacol., Biochem. Behav. 2002, 71, 533.
3. Woolley, M. L.; Marsden, C. A.; Fone, K. C. F. Curr. Drug Targets CNS Neurol.
Disord. 2004, 3, 59.
4. Mitchell, E. S.; Neumaier, J. F. Pharmacol. Ther. 2005, 108, 320.
5. Fone, K. C. F. Neuropharmacology 2008, 55, 1083.
6. Ruat, M.; Traiffort, E.; Arrang, J. M.; Tardivel-Lacombe, J.; Diaz, J.; Leurs, R.;
Schwarz, J. C. Biochem. Biophys. Res. Commun. 1993, 193, 268.
7. Kohen, R.; Metcalf, M. A.; Khan, N.; Druck, T.; Huebner, K.; Lachowicz, J. E.;
Meltzer, H. Y.; Sibley, D. R.; Roth, B. L.; Hamblin, M. W. J. Neurochem. 1996, 66,
47.
8. Rosse, G.; Schaffhauser, H. Curr. Top. Med. Chem. 2010, 10, 207.
9. Alfredo, M.; Georgina, P. G.; Ponce-Lopez, T.; Carlos, C. Int. Rev. Neurobiol. 2011,
96, 27.